CVE-2019-3895

Description

An access-control flaw was found in the Octavia service when the cloud platform was deployed using Red Hat OpenStack Platform Director. An attacker could cause new amphorae to run based on any arbitrary image. This meant that a remote attacker could upload a new amphorae image and, if requested to spawn new amphorae, Octavia would then pick up the compromised image.

Category

8.0
CVSS
Severity: High
CVSS 3.1 •
CVSS 3.0 •
CVSS 2.0 •
EPSS 0.67% Top 30%
Vendor Advisory redhat.com Vendor Advisory redhat.com
Affected: Red Hat openstack-tripleo-common
Published at:
Updated at:

References

Link Tags
https://bugzilla.redhat.com/show_bug.cgi?id=CVE-2019-3895 issue tracking third party advisory mitigation
https://access.redhat.com/errata/RHSA-2019:1683 third party advisory vendor advisory
https://access.redhat.com/errata/RHSA-2019:1742 third party advisory vendor advisory

Frequently Asked Questions

What is the severity of CVE-2019-3895?
CVE-2019-3895 has been scored as a high severity vulnerability.
How to fix CVE-2019-3895?
To fix CVE-2019-3895, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2019-3895 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2019-3895 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2019-3895?
CVE-2019-3895 affects Red Hat openstack-tripleo-common.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.